Vor Biopharma (VOR) Net Equity Issued and Repurchased (2020 - 2025)

Vor Biopharma (VOR) has 6 years of Net Equity Issued and Repurchased data on file, last reported at $49.8 million in Q4 2025.

• On a quarterly basis, Net Equity Issued and Repurchased rose 226686.36% year-over-year to $49.8 million in Q4 2025; TTM through Dec 2025 was $70.1 million, a 25393.09% increase from a year earlier, with the FY2025 full-year figure at $70.1 million, up 25393.09% from the prior year.
• Net Equity Issued and Repurchased for Q4 2025 stood at $49.8 million, up from $20.3 million in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for VOR reached as high as $49.8 million in Q4 2025 and fell as low as -$92000.0 in Q2 2024.
• Historically, Net Equity Issued and Repurchased has averaged $9.6 million across 5 years, with a median of $392000.0 in 2023.
• Across the five-year window, Net Equity Issued and Repurchased sank 115.89% in 2024 and soared 226686.36% in 2025, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $45.4 million in 2021, then plunged by 99.77% to $106000.0 in 2022, then plunged by 114.15% to -$15000.0 in 2023, then tumbled by 46.67% to -$22000.0 in 2024, then surged by 226686.36% to $49.8 million in 2025.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $49.8 million in Q4 2025, $20.3 million in Q3 2025, and -$22000.0 in Q4 2024.